Breast Care最新文献

{"title":"Granulomatous Mastitis Is Not as Benign as You Might Think: What Doctors Need to Know about the Lived Experience of People with This Rare Disease.","authors":"Mary McNaughton-Cassill, Joseph Torres, Sandra Pahl, Carolyn Cassill","doi":"10.1159/000544888","DOIUrl":"10.1159/000544888","url":null,"abstract":"<p><strong>Introduction: </strong>Granulomatous mastitis (GM) is a rare, benign disease characterized by painful inflammation, and abscesses typically on only one breast. Treatments include antibiotics, steroid treatments, and surgery, but there is no cure. The current study was designed to assess patient perceptions of living with the disease and what they would like physicians to know about their needs.</p><p><strong>Methods: </strong>The advent of the internet has enabled patients with rare conditions to reach out to support each other. Participants on a GM patient only Facebook site were asked if they would be willing to complete an anonymous survey regarding their experiences living with the disease. They completed a demographic survey, as well as measures of their pain and discomfort, psychological state, and social support.</p><p><strong>Results: </strong>The results indicated that patients with GM believe they need more help managing their pain discomfort and fatigue. They also report significant levels of depression and anxiety suggesting that they could also benefit from more psychological support.</p><p><strong>Discussion: </strong>Living with this painful, disfiguring disease for which there is no cure has a negative impact on people's mental and physical well-being. Practitioners who treat people with GM should consider providing their patients with specific pain management options, strategies for coping with fatigue and referrals to mental health practitioners who specialize in coping with chronic disease. Such efforts would help improve patient's quality of life and ability to cope with this \"benign\" but life altering disease.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 4","pages":"221-227"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144943845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference.","authors":"Nina Ditsch, Michael Gnant, Christoph Thomssen, Nadia Harbeck","doi":"10.1159/000546080","DOIUrl":"10.1159/000546080","url":null,"abstract":"<p><strong>Background: </strong>In 2025, the St. Gallen Conference was held from March 12th-15th, with the largest attendance since the pandemic and more than 3,000 participants from over 100 countries.</p><p><strong>Summary: </strong>The conference chairs professionally guided through the program on Early Breast Cancer, featuring abstracts submitted from all over the world. In addition, Prof. Dr. Herold J. Burstein (USA) led the panel through the difficult topics of local and systemic treatment modalities in an excellent, clearly structured and engaging way. Almost 80 experts from all continents and more than 30 nations formed the panel and summarized the current literature in excellent presentations and discussions.</p><p><strong>Key messages: </strong>Final voting covered the topics of genetic testing, DCIS, breast and axillary surgery, radiation therapy, systemic treatment based on subtypes, treatment of the elderly, therapy of local-regional recurrence and oligometastatic breast cancer.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"288-297"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Patient Satisfaction and Quality of Life Using the BREAST-Q Questionnaire in Oncoplastic Breast-Conserving Surgery Techniques for Centrally Located Breast Cancer.","authors":"Halit Özgül, Gülşah Çelik, Remzi Can Çakir, Ömer Çelik, Ali Çelik","doi":"10.1159/000544114","DOIUrl":"10.1159/000544114","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to retrospectively compare the impact of level-2 oncoplastic techniques - doughnut, lateral, vertical, and racket mastopexy - on patient satisfaction and quality of life in centrally located breast cancer surgery, using the BREAST-Q questionnaire.</p><p><strong>Methods: </strong>This study included patients aged 18-65 who underwent oncoplastic surgery for centrally located breast tumors at a teaching hospital between January 2021 and August 2024. The BREAST-Q questionnaire, which assesses satisfaction with the breast, psychosocial well-being, and sexual health, was administered at least 3 months post-surgery and radiotherapy. Demographic and clinical data were collected from the patient records.</p><p><strong>Results: </strong>Among the 142 patients included in the study, 90 underwent doughnut mastopexy, while 52 received other techniques. The BREAST-Q scores indicated higher satisfaction with breasts (92.28%), psychosocial well-being (87.41%), and sexual well-being (86.39%) in the doughnut mastopexy group compared to the other techniques (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Doughnut mastopexy yielded better outcomes than other techniques, likely because of minimal scarring, reduced need for contralateral procedures, and improved aesthetic results. These findings suggest that this technique offers superior patient satisfaction for centrally located breast tumors.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 3","pages":"145-153"},"PeriodicalIF":2.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025.","authors":"Tjoung-Won Park-Simon, Volkmar Müller, Ute-Susann Albert, Maggie Banys-Paluchowski, Rupert Bartsch, Ingo Bauerfeind, Vesna Bjelic-Radisic, Jens-Uwe Blohmer, Wilfried Budach, Peter Dall, Nina Ditsch, Eva M Fallenberg, Peter A Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Oleg Gluz, Nadia Harbeck, Andreas Daniel Hartkopf, Jörg Heil, Juliane Hörner-Rieber, Jens Huober, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Toralf Reimer, Mattea Reinisch, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schütz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Marion Tina van Mackelenbergh, Isabell Witzel, Achim Wöckel, Rachel Wuerstlein, Wolfgang Janni, Marc Thill","doi":"10.1159/000545019","DOIUrl":"10.1159/000545019","url":null,"abstract":"<p><p>The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2025 update of the evidence-based recommendations for the diagnosis and treatment of patients with early breast cancer.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"189-207"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11996201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Interreader Agreement between Optimized Short and Full Breast MRI Protocols for Screening Breast Cancer in Moderate- and High-Risk Women.","authors":"Agnaldo Lopes da Silva Filho, Mariana Mitraud Ottoni Guedes, Thais Paiva Moraes, Adriene Moraes Campos, Ivie Braga de Paula, Felipe Marcondes de Oliveira Coelho, Barbara Silveira Santana, Bertha Andrade Coelho, Letícia Martins de Araújo Campos Linhares, Henrique Lima Couto","doi":"10.1159/000543958","DOIUrl":"10.1159/000543958","url":null,"abstract":"<p><strong>Introduction: </strong>The optimized short breast MRI protocol for breast cancer screening was developed to address some limitations of the complete protocol, such as long examination duration and high cost. This study aimed to evaluate the intraobserver agreement between optimized short and complete protocols in the interpretation of breast MRI images. Specifically, we assessed the acquisition and reading times of the images, as well as the time required for report generation.</p><p><strong>Methods: </strong>A cross-sectional study was conducted in asymptomatic women with high breast density, at moderate and high risk, who underwent breast MRI in private institutions in Belo Horizonte, MG, Brazil. An optimized short protocol was simulated on a computer by selecting images from the complete examination. The examinations were read independently, with BI-RADS categories assigned. Intraobserver agreement between this shorter protocol and the complete protocol was assessed.</p><p><strong>Results: </strong>A total of 170 women were included. A 100% BI-RADS agreement rate was observed in categories 1 and 2, an 80.95% agreement rate in category 3, and a 93.75% agreement rate in category 4 between the protocols. The unweighted kappa value was 0.955 (95% confidence interval [CI] 0.916-0.993), while the weighted kappa value was 0.969 (95% CI: 0.943-0.995). Furthermore, the optimized short protocol reduced examination duration by 21 min.</p><p><strong>Conclusion: </strong>The optimized short breast MRI protocol provides a time-efficient alternative for breast cancer screening in moderate- to high-risk populations with dense breasts while maintaining strong agreement in BI-RADS classification. This protocol reduces costs and enhances patient tolerability, thereby improving accessibility to breast MRI.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"163-169"},"PeriodicalIF":2.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life in Patients Pre- and Post-Breast Reduction Surgery in a South African Population: A Single-Centred Patient-Based Study.","authors":"Nokubonga Khwela, Anil Madaree, Nivana Mohan, Lelika Lazarus","doi":"10.1159/000543306","DOIUrl":"10.1159/000543306","url":null,"abstract":"<p><strong>Introduction: </strong>Breast hypertrophy is the abnormal enlargement of breast tissue resulting in extremely large breasts and is a regular condition among women worldwide. It can affect different aspects of their life, including their psycho-social, sexual, emotional, and physical well-being. This study aimed to assess the quality of life in individuals with breast hypertrophy both before and after undergoing breast reduction surgery.</p><p><strong>Methods: </strong>Two sets of questionnaires (preoperative and post-operative) were formulated and distributed to 18 patients (median age of 31, age range: 18-48 years) undergoing breast reduction surgery. Patients were also provided with an informed consent form.</p><p><strong>Results: </strong>Preoperatively, most patients expressed different levels of dissatisfaction with themselves across all categories. However, post-operatively, significant levels (<i>p</i> < 0.05, <i>p</i> < 0.001) of satisfaction were demonstrated by patients, as 100% of them reported a reduction in back pain and heaviness of breasts, and 100% reported improvement in their self-confidence. Also, 94% and 65% reported improvement in their social interaction and sexual life, respectively, while 83% and 61% of patients reported satisfaction in carrying their grocery shopping bags and their engagement in regular exercise programs, respectively.</p><p><strong>Conclusion: </strong>The study illustrates that breast reduction surgery had a positive effect on the quality of life of patients as a significant proportion of them reported improvement and satisfaction across all categories following the procedure.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"170-181"},"PeriodicalIF":2.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-Fraction External Beam Radiotherapy in Patients with Early Breast Cancer.","authors":"Budhi Singh Yadav, Habeeb Kudukkil Appakattu Kuzhi, Divya Dahiya, Monsu Rathod, Arun Oinam Singh, Gaganpreet Singh","doi":"10.1159/000543855","DOIUrl":"10.1159/000543855","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with early breast cancer (EBC) can be treated with accelerated partial breast irradiation (APBI). The objective of this study was to determine if a three-fraction APBI schedule is feasible for these patients.</p><p><strong>Methods: </strong>This single-institutional, phase 2 study included patients with age ≥45 years, tumor size <3.5 cm, negative nodes, negative surgical margins, and unicentric tumors. Patients were treated with 3D-CRT technique with a dose of 22.5 Gy in 3 fractions on 3 consecutive days. The primary end point of the study was cosmesis as assessed by physicians at 3 years. Secondary end points were cosmesis as assessed by patients, dosimetry, acute and late toxicities, disease-free and overall survival.</p><p><strong>Results: </strong>From October 2019 to October 2022, 49 patients were treated. Mean age of the patients was 55 years (range 40-75). At 3 years, physician- and patient-reported cosmetic results were excellent/good/fair in 33 (67%)/14 (29%)/2 (4%) of patients and in 29 (59%)/16 (33%)/4 (8%) of patients, respectively. Acute dermatitis grades 1 and 2 were observed in 14 (29%) and 3 (6%) of patients, respectively. At 6 months, breast edema, skin induration, subcutaneous fibrosis, pain, and pigmentation were observed in 3 (6%), 6 (12%), 3 (6%), 2 (4%), and 8 (16%) of patients, respectively. At 3 years, 1 (2%) patient had mild pain; no breast edema, skin induration, subcutaneous fibrosis, or pigmentation was observed. At a median follow-up of 39 months (range 24-60), there were no local/regional recurrences. One patient developed distant metastases in the bones, liver, and lungs at 46 months. All patients were alive at last follow-up.</p><p><strong>Conclusion: </strong>In patients with EBC, three-fraction APBI is feasible. Physician- and patient-reported cosmesis was excellent/good in 96% and 92% of patients, respectively. Late effects were only grade 1.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 3","pages":"154-162"},"PeriodicalIF":2.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025.","authors":"Marc Thill, Wolfgang Janni, Ute-Susann Albert, Maggie Banys-Paluchowski, Rupert Bartsch, Ingo Bauerfeind, Vesna Bjelic-Radisic, Jens Blohmer, Wilfried Budach, Peter Dall, Nina Ditsch, Eva Maria Fallenberg, Peter A Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Oleg Gluz, Nadia Harbeck, Andreas Hartkopf, Jörg Heil, Juliane Hörner-Rieber, Jens Huober, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Mattea Reinisch, Toralf Reimer, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schütz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Marion van Mackelenbergh, Isabell Witzel, Achim Wöckel, Rachel Würstlein, Volkmar Müller, Tjoung-Won Park-Simon","doi":"10.1159/000545018","DOIUrl":"10.1159/000545018","url":null,"abstract":"<p><p>The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO; German Gynecological Oncology Group) presents the 2025 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer (mBC).</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"208-219"},"PeriodicalIF":2.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyoderma Gangrenosum of the Breast: A Diagnostic Challenge.","authors":"Joaquim Marcoval, Clara Muntaner-Virgili, Júlia Boronat-Cucarull, Marta Gangonells-Dols, Alvaro Lagos-Tapia","doi":"10.1159/000544905","DOIUrl":"10.1159/000544905","url":null,"abstract":"<p><strong>Introduction: </strong>Pyoderma gangrenosum (PG) is a rare, noninfectious neutrophilic dermatosis usually located in the legs. PG of the breast is infrequent and may be a diagnostic challenge. Our objective was to review our patients with breast PG in order to analyse their clinical features.</p><p><strong>Methods: </strong>Patients diagnosed with PG involving the breast in Bellvitge University Hospital (Barcelona, Spain) between 2000 and 2023 were included in the study. Medical charts were retrospectively reviewed to obtain clinical data.</p><p><strong>Results: </strong>Ten patients were diagnosed with breast PG (10 women aged between 30 and 63 years, median 49.5). Evolution time at diagnosis ranged between 4 days and 7 months. In all cases, PG lesions were painful. All patients presented ulcerated lesions. In 2 cases, nodular abscess-like lesions and cribriform scars were also observed. The nipple was involved in 4 cases. Two patients had underlying diseases recognized as frequently associated with PG (ulcerative colitis and rheumatoid arthritis). Seven patients had a previous breast surgery that was considered related to PG (removal of breast carcinoma with breast reconstruction in 6 cases and breast reduction in one). The diagnosis of postsurgical breast PG was delayed in 6 patients by between 3 and 7 months. One patent developed radiation therapy induced pathergy after healing of postsurgical PG.</p><p><strong>Conclusion: </strong>The most common triggering factor for breast PG in our study was reconstruction following surgery for breast carcinoma. Medical professionals who treat breast diseases should be aware of this disease in order to lessen diagnostic delay.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 3","pages":"182-188"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Assessment Using Gene Expression Profiling Correlates with Clinical Prognosis Estimation in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer.","authors":"Alexa Binder, Kristina Tendl-Schulz, Maximilian Marhold, Kerstin Wimmer, Margaretha Rudas, Rupert Bartsch, Zsuzsanna Bago-Horvath, Elisabeth S Gruber, Ruth Exner","doi":"10.1159/000545785","DOIUrl":"10.1159/000545785","url":null,"abstract":"<p><strong>Background: </strong>Gene expression profiles (GEPs) are recommended for tailoring adjuvant treatment in patients with hormone receptor (HR)-positive/HER2-negative breast cancer (BC) with intermediate clinical and pathological risk. This single-center retrospective study aimed at evaluating the clinical relevance of the additive information provided by GEPs in clinical routine at a tertiary care center.</p><p><strong>Methods: </strong>From 03/2010 to 07/2019, GEPs by either MammaPrint (MP) or PAM50 of HR-positive/HER2-negative early-stage BC were retrospectively included in the study. Pseudonymized data were processed for statistical analysis. Correlations between clinical and molecular risk markers were calculated. Survival was estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>Clinical and molecular risk data were available for 213 patients; complete follow-up data were available for 189 patients. According to GEPs by either MP (<i>n</i> = 69) or PAM50 (<i>n</i> = 144), 67 patients (31.5%) had low, 58 (27.2%) intermediate only in PAM50, and 88 (41.3%) high-risk BC. The MP group showed a higher rate of molecular low-risk tumors, while tumors analyzed by PAM50 were more frequent in a molecular high-risk situation. A significant correlation of proliferation rate and grading with the molecular risk score was observed (<i>p</i> < 0.001 each). Adjuvant chemotherapy was recommended in 87.5% of molecular high-risk tumors but administered in 64.8% only. Interestingly, a worse DFS was detected in the molecular low-risk group compared to the high-risk group (<i>p</i> = 0.55). It may be assumed that this is associated with an advanced tumor stage in these patients.</p><p><strong>Conclusion: </strong>In HR-positive/HER2-negative BC, proliferation rate as well as tumor grade correlated significantly with risk assessment by GEPs. Despite a high-risk result, chemotherapy is often omitted due to patient-specific factors such as age, comorbidities, or patients' preference. On the other hand, survival with genomic low-risk tumors is likely to be compromised to more advanced stage, questioning the clinical validity of GEPs in these cases.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-8"},"PeriodicalIF":2.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}